Ambit Biosciences Corp  

(Public, NASDAQ:AMBI)   Watch this stock  
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -1.42
Shares 18.00M
Beta     -
Inst. own 87%

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -31869.23% -41.55%
Operating margin -40603.85% -25.96%
EBITD margin - -33.79%
Return on average assets -55.41% -23.96%
Return on average equity -72.76% -
Employees 53 -
CDP Score - -


11080 Roselle St
SAN DIEGO, CA 92121-1233
United States - Map
+1-858-3342100 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company’s lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company’s second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company’s third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.